In-licensing and product development opportunities available
Similasan’s Dutch subsidiary – Similasan Nederland BV – has marked the one-year anniversary of their re-launch by welcoming three new dry eye products into their portfolio.
Originally launching with four Similasan medical devices for tired, irritated and itchy eyes in 2014, the new ‘Similasan Optimoist’ range is specifically for use with dry eyes. Available now, products include Similasan Optimoist Drops (10mls), Similasan Optimoist Singles (10 x 0.4ml) and a Similasan Optimoist 2-in-1 Dry & Irritated Spray (10mls).
The Netherland’s team, headed up by Harm-Jan Schuurman, an experienced operator in the consumer health products industry have been working closely with GBT Pharma on the re-launch programme.
“GBT Pharma has been instrumental in helping us facilitate our re-entry into the Netherlands,” comments Harm-Jan. “Their experience of helping consumer healthcare companies expand into new markets is unrivalled. From regulatory know-how, to developing new product opportunities, we can count on them to ensure we have the right strategy for success.”
“Harm and his team have achieved a phenomenal amount in a short timeframe, not least re-establishing Similasan among the top five eye care brands in the Dutch market, in the space of only a year,” comments GBT Pharma founder Gian Trepp.
“The future holds many exciting opportunities, as Harm and his team continue on their mission to further drive market growth. As well as working alongside the team to grow the Similasan brand in the Netherlands we will also be offering in-licensing and product development opportunities,” adds Gian.
Parties interested in listing the Similasan eye care range, or to discuss in-licensing opportunities should contact Gian Trepp.
Companies in the Netherlands seeking help and advice with their consumer healthcare strategy are invited to visit OTC-Labs BV – www.otc-labs.nl
OTC labs is a specialist consultancy helping consumer healthcare companies build long term success for their OTC brands.